Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in Advanced Cancer with Krebs Cycle Alterations
NCT05904457Phase 2Recruiting
- Sponsor
- Asan Medical Center
- Start
- Jan 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in solid tumor (advanced stage), sponsored by Asan Medical Center. Started Jan 2023; status: recruiting.
02
Drugs
bevacizumaberlotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05904457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904457.